Related Experiment Video
Updated: Oct 7, 2025

An Aptamer-based Sensor for Unchelated GadoliniumIII
Published on: January 9, 2017
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration
Julie Davies1, Petra Siebenhandl-Wolff2, Francois Tranquart2
1GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK. julie.davies@ge.com.
Abstract:
Gadolinium-based contrast agents (GBCAs) have transformed magnetic resonance imaging (MRI) by facilitating the use of contrast-enhanced MRI to allow vital clinical diagnosis in a plethora of disease that would otherwise remain undetected. Although over 500 million doses have been administered worldwide, scientific research has documented the retention of gadolinium in tissues, long after exposure, and the discovery of a GBCA-associated disease termed nephrogenic systemic fibrosis, found in patients with impaired renal function. An understanding of the pharmacokinetics in humans and animals alike are pivotal to the understanding of the distribution and excretion of gadolinium and GBCAs, and ultimately their potential retention. This has been well studied in humans and more so in animals, and recently there has been a particular focus on potential toxicities associated with multiple GBCA administration. The purpose of this review is to highlight what is currently known in the literature regarding the pharmacokinetics of gadolinium in humans and animals, and any toxicity associated with GBCA use.
More Related Videos
Related Concept Videos
Imaging Studies III: Computed Tomography
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Radiological Investigation I: X-ray and CT
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

